Skip to main content
main-content

Bladder cancer

Treatment

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

23-01-2018 | Bladder cancer | Article

Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy

Cheng W et al. Oncogenesis 2018; 7: 2. doi:10.1038/s41389-017-0013-7

31-10-2017 | Bladder cancer | Article

The anti-PD-1 era — an opportunity to enhance radiotherapy for patients with bladder cancer

Nat Rev Urol 2017. doi:10.1038/nrurol.2017.172

Screening, diagnosis and staging

31-01-2018 | Bladder cancer | Article

A practical guide to bladder cancer pathology

Compérat E et al. Nat Rev Urol 2018; doi:10.1038/nrurol.2018.2

02-01-2018 | Bladder cancer | Article

Characteristics and clinical significance of histological variants of bladder cancer

​​​​​​​Nat Rev Urol 2017; 14:651–668. doi:10.1038/nrurol.2017.125

17-07-2017 | Bladder cancer | Article

Advances in imaging in prostate and bladder cancer

Srivastava A, Douglass LM, Chernyak V et al. Curr Urol Rep 2017;18:69. doi:10.1007/s11934-017-0718-3

Epidemiology and prevention

01-11-2016 | Genitourinary cancers | Article

Smoking status, usual adult occupation, and risk of recurrent urothelial bladder carcinoma: data from The Cancer Genome Atlas (TCGA) Project

Wilcox AN et al. Cancer Causes Control 2016; 27: 1429–1435. doi:10.1007/s10552-016-0821-7

21-03-2016 | Genitourinary cancers | Article

Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses

Al-Zalabani AH et al. Eur J Epidemiol 2016; 31: 811–851. doi:10.1007/s10654-016-0138-6

19-02-2016 | Genitourinary cancers | Article

Diabetes pharmacotherapies and bladder cancer: a Medicare epidemiologic study

Mackenzie TA et al. Diabetes Ther 2016;7:61–73. doi:10.1007/s13300-016-0152-4

01-09-2015 | Genitourinary cancers | Article

Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’

Ptaszynska A et al. Diabetes Ther 2015;6:357–375. doi:10.1007/s13300-015-0128-9